Effects of cessation of terbutaline treatment on airway obstruction and responsiveness in patients with chronic obstructive pulmonary disease

Thorax

Volumn 51, Issue 7, 1996, Pages 684-688

  De Jong, Jan W ^a   Koëter, Gerard H ^a   Van Der Mark, Thomas W ^a   Postma, Dirkje S ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Chronic obstructive pulmonary disease; Rebound airway responsiveness; Rebound bronchoconstriction; Terbutaline

Indexed keywords

IPRATROPIUM BROMIDE; PLACEBO; TERBUTALINE;

ADULT; AGED; AIRWAY OBSTRUCTION; ARTICLE; BRONCHOSPASM; BRONCHUS REACTIVITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG WITHDRAWAL; FEMALE; HUMAN; INHALATIONAL DRUG ADMINISTRATION; LUNG FUNCTION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REBOUND;

EID: 0030012347     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.51.7.684     Document Type: Article

References (17)

1. Spitzer WO, Suissa S, Ernst P, Horwitz RI, Habbick B, Cockcroft D, et al. The use of β-agonists and the risk of death and near death from asthma. N Engl J Med 1992; 326:501-6.
2. Vathenen AS, Knox AJ, Higgins BG, Britton JR, Tattersfield AK. Rebound increase in bronchial responsiveness after treatment with inhaled terbutaline. Lancet 1988;i:554-8.
3. 2-agonist treatment. Am Rev Respir Dis 1993; 148:707-12.
4. Karpel JP. Bronchodilator responses to anticholinergic and β-adrenergic agents in acute and stable COPD. Chest 1991;99:871-6.
5. Postma DS, de Vries K, Koëter GH, Sluiter HJ. Independent influence of reversibility of airflow obstruction and non-specific hyperreactivity on the long-term course of lung function in chronic airflow obstruction. Am Rev Respir Dis 1986;134:276-80.
6. van Schayck CP, Dompeling E, van Herwaarden CLA, Folgering H. Verbeek ALM, van der Hoogen HJM, et al. Bronchodilator treatment in moderate asthma or chronic bronchitis: continuous or on demand? A randomised controlled study. BMJ 1991;303:1426-31.
7. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 1987;136:225-44.
8. Quanjer PhH. Standardised lung function testing. Bull Eur Physiopathol Respir 1983;19(Suppl 5):7-28.
9. Sterk PJ, Fabbri LM, Quanjer PhH, Cockcroft DW, O'Byrne PM, Anderson SD, et al. Airway responsiveness. Standardized challenge testing with pharmacological, physical and sensitizing stimuli in adults, Eur Respir J 1993;6(Suppl 16):53-83.
10. The SAS System for Windows 3·10, release 6·08, Cary, North Carolina, USA: SAS Institute Inc, 1992.
11. Ollerenshaw SL, Woolcock AJ. Characteristics of the inflammation in biopsies from large airways of subjects with asthma and subjects with chronic airflow limitation. Am Rev Respir Dis 1992;145:922-7.
12. 2-agonist salbutamol (albuterol) on bronchoconstriction provoked by histamine, methacholine, and adenosine 5′-monophosphate in asthma. J Allergy Clin Immunol 1990;85:755-62.
13. 2-agonists in asthma. N Engl J Med 1992;327:1204-8.
14. de Jong JW, van der Mark ThW, Koëter GH, Postma DS. Rebound airway obstruction and responsiveness after cessation of terbutaline treatment: effects of budesonide. Am J Respir Crit Care Med 1996;153:70-5.
15. Nijkamp FP, Engels F, Henricks PAJ, van Oosterhout AJM. Mechanisms of β adrenergic receptor regulation in lungs and its implications for physiological responses. Physiol Rev 1992;72:323-57.
16. Ullah ML, Newman GB, Saunders K. Influence of age on response to ipratropium and salbutamol in asthma. Thorax 1981;36:523-9.
17. van Schayck CP, Dompeling E, van Herwaarden CLA, Folgering H, Akkermans RP, van den Broek PJA, et al. Continuous use of bronchodilators versus use on demand in mild asthma and COPD. Am J Respir Crit Care Med 1994;149:A203.